IDEXX Laboratories Inc (IDXX) Fair Value & Analysis
Healthcare · US · Market cap $45.4B · ISIN US45168D1046
What is IDEXX Laboratories Inc really worth?
IDEXX Laboratories Inc
IDXX · US
A strong business, but trading 107% above our fair value of $255.77.
Strengths
Risks
Fair value as of: Sep 2, 2026
From 26 valuation models · updated 2 days ago
Share price −10.0% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 85/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case ($322.55). The favourable scenario is already priced in.
- A fairly wide model range ($154.72 to $322.55) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 2, 2026.
How to read this chart
60‑month range $324.64 – $766.68 · fair‑value band $154.72 – $322.55 · the $529.29 price screens above the $255.77 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 2, 2026.
Analysis
IDEXX Laboratories Inc (IDXX) currently trades at $529.29, while our model-based Fair Value estimate is $255.77, implying the stock looks roughly 107.0% overvalued today. The Quality Score stands at 85/100 (high quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $291.79 per share, and 0 of the 26 models we run sit above the $529.29 price. Bear case: the Earnings-Based group reads lowest at $144.78, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, IDEXX Laboratories Inc generated revenue of $4.4B at a net margin of 24.6%. Revenue grew 14.3% year over year. It earns a return on equity of 72.9%. Net debt stands at $897M. Fundamentals as of Sep 2, 2026
Our scenario range runs from $154.72 (bear case) to $322.55 (bull case); at $529.29, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −52% fair-value upside, at −52%, IDXX screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $9.55 per share, which is 3.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models ($291.79) versus Dividend Discount ($9.50). Highest evidence: FCF DCF (78).
Notify me when IDXX reaches fair value
Put IDXX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 81 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Full company description
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IDEXX Laboratories Inc reported revenue of $4.3B in FY2025 versus $3.2B in FY2021, a compound +7.6%/yr. Reported net income was $1.1B in FY2025, compounding +9.2%/yr from FY2021.
of which total revenue +10.4 % · buybacks/dilution +1.6 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
IDXX screens 107% overvalued. Compare with Thermo Fisher Scientific Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
- Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
- Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
- IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Peer Group
Diagnostics & Research · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 44/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Sep 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | −51% |
| Danaher Corporation DHR | $215.68 | $103.88 | −52% |
| WuXi AppTec Co 2359 | HK$189.30 | HK$150.16 | −21% |
| Lonza Group LONN | CHF 576.60 | CHF 259.80 | −55% |
| Agilent Technologies, Inc A | $149.93 | $61.53 | −59% |
| Waters Corporation WAT | $416.15 | $121.96 | −71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | −44% |
| Illumina, Inc ILMN | $215.59 | $95.51 | −56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | −57% |
| Quest Diagnostics Incorporated DGX | $242.76 | $162.50 | −33% |
Compare IDEXX Laboratories Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is IDEXX Laboratories Inc (IDXX) overvalued or undervalued?
What is the fair value of IDXX?
What is the quality score of IDXX?
What is the revenue of IDEXX Laboratories Inc (IDXX)?
What is the net profit margin of IDXX?
Does IDEXX Laboratories Inc pay a dividend?
Watch IDEXX Laboratories Inc in the live analysis
One click puts IDEXX Laboratories Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.